Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Other Non-Current Liabilities of $453000.0 for Q1 2026, down 47.08% year-over-year from $856000.0 in Q1 2025, and down 18.53% quarter-over-quarter from $556000.0 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Foghorn Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $453000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 47.08% year-over-year to $453000.0; the TTM figure through Mar 2026 stood at $453000.0 (down 47.08% YoY), while the FY2025 annual figure was $556000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $453000.0, down from $556000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $856000.0 in Q1 2025, with the low at $29000.0 in Q4 2022.
- The 3-year median for Other Non-Current Liabilities is $453000.0 (2026), against an average of $396555.6.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities tumbled 79.72% in 2022, then plunged 47.08% in 2026.
- Foghorn Therapeutics' Other Non-Current Liabilities stood at $29000.0 in 2022, then soared by 1817.24% to $556000.0 in 2025, then declined by 18.53% to $453000.0 in 2026.
- Business Quant data shows FHTX's Other Non-Current Liabilities at $453000.0 in Q1 2026, $556000.0 in Q4 2025, and $656000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 347.14 Mn | 279.06 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 350,000.00 |
| Mar 31, 2026 | 453,000.00 |
| Dec 31, 2025 | 556,000.00 |
| Sep 30, 2025 | 656,000.00 |
| Jun 30, 2025 | 757,000.00 |
| Mar 31, 2025 | 856,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 58,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 116,000.00 |
| Dec 31, 2021 | 143,000.00 |
| Sep 30, 2021 | 171,000.00 |